The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
LabCorp will operate SBMF's former clinical lab in South Bend, Indiana, and the two parties will collaborate to provide integrated pathology services.
Quest said it will not acquire True Health's facilities or staff and that it expects the buy to expand the reach of its cardio-metabolic diagnostic services.
Progenity gains 137 granted patents and 15 pending applications in the US, Europe, China, and Japan in the deal.
The combined company will offer laboratory testing and digital technologies for diagnosing and managing lupus, multiple sclerosis, and other autoimmune diseases.
Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
According to PathGroup, the deal will broaden its testing menu and adds more than 120 pathologists covering all pathology sub-specialties to the company.
As part of the agreement, Sienna will acquire the intellectual property assets and certain laboratory equipment from Sevident for cash and company scrip.
The company plans to launch on the platform tests for diagnosing sexually transmitted diseases and for distinguishing between viral and bacterial infections.
The agreement, which includes an exclusive provider relationship with Boyce and Bynum's anatomic pathology division in Missouri, deepens Quest's Midwest presence.